RE-BVS – Piemonte Repository

Sfoglia per AUTORE
ROSSETTI B
Collezione ASL Città di Torino

Items : 7

Comparison of Different HIV-1 Resistance Interpretation Tools for Next-Generation Sequencing in Italy. in Viruses / Viruses. 2024 Sep 6;16(9):1422. doi: 10.3390/v16091422.

2024
ASL Città di Torino

Armenia D; Carioti L; Micheli V; Bon I; Allice T; Bonura C; Bruzzone B; Bracchitta F; Cerutti F; Giammanco GM; Stefanelli F; Bonifacio MA; Bertoli A; Vatteroni M; Ibba G; Novazzi F; Lipsi MR; Cuomo N; Vicenti I; Ceccherini-Silberstein F; Rossetti B; Bezenchek A; Saladini F; Zazzi M; Santoro MM;

Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells. in The Journal of general virology / J Gen Virol. 2021 Jan;102(1). doi: 10.1099/jgv.0.001499.

2021
ASL Città di Torino

Vicenti I; Dragoni F; Monti M; Trombetta CM; Giannini A; Boccuto A; Saladini F; Rossetti B; De Luca A; Ciabattini A; Pastore G; Medaglini D; Orofino G; Montomoli E; Zazzi M;

Patient-Reported Outcomes in an Observational Cohort of HIV-1-Infected Adults on Darunavir/Cobicistat-Based Regimens: Beyond Viral Suppression. in The patient / Patient. 2020 Jun;13(3):375-387. doi: 10.1007/s40271-020-00413-y.

2020
ASL Città di Torino

Antinori A; Cossu MV; Menzaghi B; Sterrantino G; Squillace N; Di Cristo V; Cattelan A; Focà E; Castagna A; Orofino G; Valenti D; D'Ettore G; Aprea L; Ferrara S; Locatelli ME; Madeddu G; Pontali E; Scerbo P; Rossetti B; Uglietti A; Termini R; Rucci F; Gori A; Mancusi D;

Correction to: Patient-Reported Outcomes in an Observational Cohort of HIV-1-Infected Adults on Darunavir/Cobicistat-Based Regimens: Beyond Viral Suppression. in The patient / Patient. 2020 Aug;13(4):469-470. doi: 10.1007/s40271-020-00425-8.

2020
ASL Città di Torino

The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study. in Journal of acquired immune deficiency syndromes (1999) / J Acquir Immune Defic Syndr. 2019 May 1;81(1):e17-e21. doi: 10.1097/QAI.0000000000001986.

2019
ASL Città di Torino

Rossetti B; Gagliardini R; Sterrantino G; Colangeli V; Latini A; Colafigli M; Vignale F; Rusconi S; Di Biagio A; Orofino G; Mezzaroma I; Vullo V; Francisci D; Mastroianni C; Trezzi M; Canovari B; Lamonica S; Ciccullo A; Borghetti A; D?Arminio Monforte A; Di Giambenedetto S; De Luca A;

Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial. in PloS one / PLoS One. 2017 Nov 21;12(11):e0187393. doi: 10.1371/journal.pone.0187393. eCollection 2017.

2017
ASL Città di Torino

Rossetti B; Gagliardini R; Meini G; Sterrantino G; Colangeli V; Re MC; Latini A; Colafigli M; Vignale F; Rusconi S; Micheli V; Di Biagio A; Orofino G; Ghisetti V; Fantauzzi A; Vullo V; Grima P; Francisci D; Mastroianni C; Antinori A; Trezzi M; Lisi L; Navarra P; Canovari B; D'Arminio Monforte A; Lamonica S; D'Avino A; Zazzi M; Di Giambenedetto S; et alii...

Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study. in Journal of the International AIDS Society / J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19818. doi: 10.7448/IAS.17.4.19818. eCollection 2014.

2014
ASL Città di Torino

Gagliardini R; Rossetti B; Bianco C; Rusconi S; Colafigli M; Prinapori R; Francisci D; Fantauzzi A; Orofino G; Vignale F; Di Giambenedetto S; De Luca A;